WO2001068070A3 - Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis - Google Patents

Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis

Info

Publication number
WO2001068070A3
WO2001068070A3 PCT/IT2001/000113 IT0100113W WO0168070A3 WO 2001068070 A3 WO2001068070 A3 WO 2001068070A3 IT 0100113 W IT0100113 W IT 0100113W WO 0168070 A3 WO0168070 A3 WO 0168070A3
Authority
WO
WIPO (PCT)
Prior art keywords
spirolaxin
treatment
diseases associated
abnormal angiogenesis
angiogenesis
Prior art date
Application number
PCT/IT2001/000113
Other languages
French (fr)
Other versions
WO2001068070A8 (en
WO2001068070A2 (en
Inventor
Sergio Penco
Claudio Pisano
Giuseppe Giannini
Original Assignee
Sigma Tau Ind Farmaceuti
Sergio Penco
Claudio Pisano
Giuseppe Giannini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti, Sergio Penco, Claudio Pisano, Giuseppe Giannini filed Critical Sigma Tau Ind Farmaceuti
Priority to AU44533/01A priority Critical patent/AU4453301A/en
Publication of WO2001068070A2 publication Critical patent/WO2001068070A2/en
Publication of WO2001068070A8 publication Critical patent/WO2001068070A8/en
Publication of WO2001068070A3 publication Critical patent/WO2001068070A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The use is described of spirolaxin having formula (I) as a compound useful for the preparation of a drug with antiangiogenic activity.
PCT/IT2001/000113 2000-03-13 2001-03-07 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis WO2001068070A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44533/01A AU4453301A (en) 2000-03-13 2001-03-07 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2000A000129 2000-03-13
IT2000RM000129A IT1317001B1 (en) 2000-03-13 2000-03-13 USE OF SPIROLAXIN FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH AN ALTERED ANGIOGENESIS.

Publications (3)

Publication Number Publication Date
WO2001068070A2 WO2001068070A2 (en) 2001-09-20
WO2001068070A8 WO2001068070A8 (en) 2001-11-08
WO2001068070A3 true WO2001068070A3 (en) 2002-04-18

Family

ID=11454527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2001/000113 WO2001068070A2 (en) 2000-03-13 2001-03-07 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis

Country Status (3)

Country Link
AU (1) AU4453301A (en)
IT (1) IT1317001B1 (en)
WO (1) WO2001068070A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010136A1 (en) 2001-03-16 2002-09-16 Sigma Tau Ind Farmaceuti USEFUL COMPOUNDS FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE ACTIVATION OF THE PPAR-GAMMA RECEPTOR.
ITMI20041279A1 (en) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd USE OF TRIFLUOROACETATE CALCIUM FOR THE PREPARATION OF ANTI-ANGIOGENETIC EFFECT MEDICATIONS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005204A1 (en) * 1994-08-09 1996-02-22 Pfizer Inc. Spirolaxine derivatives for treating gastroduodenal diseases
JPH107557A (en) * 1996-06-17 1998-01-13 Banyu Pharmaceut Co Ltd Antitumor substance spirolaxine
WO2000003726A1 (en) * 1998-07-14 2000-01-27 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005204A1 (en) * 1994-08-09 1996-02-22 Pfizer Inc. Spirolaxine derivatives for treating gastroduodenal diseases
JPH107557A (en) * 1996-06-17 1998-01-13 Banyu Pharmaceut Co Ltd Antitumor substance spirolaxine
WO2000003726A1 (en) * 1998-07-14 2000-01-27 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 05 30 April 1998 (1998-04-30) *

Also Published As

Publication number Publication date
ITRM20000129A0 (en) 2000-03-13
WO2001068070A8 (en) 2001-11-08
IT1317001B1 (en) 2003-05-26
AU4453301A (en) 2001-09-24
WO2001068070A2 (en) 2001-09-20
ITRM20000129A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
AU1025795A (en) Prolineamide derivatives
AU1529901A (en) Compounds
GB0105772D0 (en) Use
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
WO2002039954A3 (en) Novel compounds
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
WO2002011737A3 (en) Anti-inflammatory medicament
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
WO2002026732A1 (en) Benzodiazepine derivative
WO2001016096A3 (en) Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia
WO2001068070A8 (en) Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
WO2003063858A3 (en) Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases
WO1998056759A3 (en) Novel pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same
AU1651201A (en) Amidinophenylpyruvic acid derivative
WO2003091243A8 (en) Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
WO2000076966A3 (en) Indolinylamide derivatives and the use thereof as antiviral drugs
WO2001068071A3 (en) Use of natural chrysanthone compounds having antiangiogenic activity
NO20021710D0 (en) Use of 2-amino-3,4-dihydroquinazolines for the preparation of a medicament for the treatment or prophylaxis of diseases caused by ischemic conditions
NO20014889D0 (en) Process for the preparation of medical agents
WO2004035031A3 (en) Treatment of uveal melanoma
EP1464636A4 (en) Novel substance having antitumor/anti-inflammatory activity
AU1434201A (en) Antithrombotic agents
WO2000046193A3 (en) Ether derivatives having neuronal activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP